comprehensive -WSS

comprehensive

author：hotspot 2025-10-03 00:06:39 - browse：7582

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Information blocking fines are now fair game in health care

knowledge

focus

WSS

How climate

Covid’s new normal has set in amid another rise in cases

Fed up with FDA, ALS advocates consider a take

Why the quest to eradicate polio has stumbled

Pharmacists can make shortage drugs, but at what cost?

Hospital price transparency does save money, advocate argues

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Hospital price transparency does save money, advocate argues

Wildfire smoke exposes gaps in outdoor worker protections

Fed up with FDA, ALS advocates consider a take

Anesthesiologist group: stop taking Ozempic before surgery

Pharmacists can make shortage drugs, but at what cost?

After affirmative action ruling, medical educators look to 'holistic review'

PBMs drew scrutiny in House hearing — and so did pharma

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why the quest to eradicate polio has stumbled

Wikipedia

How the messy conversation about Dolly changed bioethics

STAT Readout Newsletter: Today's biggest biotech updates

CEOs share strategies for surviving biotech slump

Why the quest to eradicate polio has stumbled

Impact of Dobbs ruling felt at reproductive medicine meeting

Midwives could help bridge maternal health disparities in the U.S.

knowledge

explore

focus

hotspot